BOSTON, April 08, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, today reported fourth quarter and full year 2023 financial results. Presented additional positive data from the ongoing Phase 1 trials of CUE-101 in first line (1L) human papillomavirus positive (HPV+) recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in combination with ...

✓ Generation of a Therapeutic Index for IL-2 > Selective targeting of IL-2 to tumor-specific T cells ✓ Clinical Validation and PoC (>100 Patients Treated) > Monotherapy activity in late-stage cancer patients > Potential doubling of ORR and mPFS in combination with CPI ์ Favorable Tolerability Profile ✓ Strong Metrics of Manufacturability Flexible Platform with Potential Regulatory Advantages The structural design of our IL-2 based CUE-100 series antibody-based molecules enables modularity of the various com ...

BOSTON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively modulate disease-specific T cells, announced today that the company's lead clinical asset, CUE-101, will be featured in a presentation at the 2024 Multi-disciplinary Head and Neck Cancers Symposium given by Alexander Dimitrios Colevas, M.D., a principal investigator at Stanford University participating in the CUE-101 clinical ...

There are four predominant and core features to highlight. First, as noted in this slide, we have created a therapeutic index for IL-2 by selectively targeting tumor-specific T-cells through the T-cell receptor, or TCR, that provides the highest degree of specificity for the desired T-cells relevant to antitumor immunity. When we refer to a therapeutic index, this basically refers to the ability to dose patients at a range of doses whereby they experience demonstrable clinical benefit, example, an increase ...

Financing Activities During the nine months ended September 30, 2023 and 2022, we generated cash from financing activities of $7,078,000 and $26,256,000, respectively, a decrease of $19,178,000. Cash from financing activities during the nine months ended September 30, 2023 consisted of cash proceeds from the sale of common stock pursuant to the October 2021 ATM Agreement of $7,605,000 net of sales agent commissions and fees, and cash proceeds from the exercise of stock options of $473,000. Cash from financi ...

Company Participants Anish Suri - President & Chief Scientific Officer Kerri Millar - Chief Financial Officer Ted Tenthoff - Piper Sandler Operator I would now like to turn the conference over to Dan Passeri, Cue BiopharmaÂ's Chief Executive Officer. Thank you. You may begin. Hi. Thank you very much, and good afternoon, everyone. As a reminder, this presentation and discussions being recorded and will be available on our website for the next 30 days. Also please be aware that the slide accompanying todayÂ's ...

| --- | --- | --- | --- | --- | |-------------------------------------|-------|-----------------------|------------|---------------------| | | | June 30, 2023 \n(in | thousands) | December 31, 2022 | | Laboratory equipment | $ | 5,205 | $ | 5,246 | | Furniture and fixtures | | 81 | | 81 | | Computer and office equipment | | 296 | | 296 | | Leasehold improvements | | 118 | | 118 | | | | 5,699 | | 5,741 | | Less accumulated depreciation | | (4,507 | ) | (4,242 ) | | Net property and equipment | $ | 1,192 | $ ...

Principal Commitments As a smaller reporting company, we are not required to provide the information required by this Item 3. Inherent Limitations on Effectiveness of Controls PART II. OTHER INFORMATION We operate in a rapidly changing environment that involves a number of risks that could materially affect our business, financial condition or future results, some of which are beyond our control. The occurrence of any of these risks could harm our business, financial condition, results of operations and/or ...

Sure. All right. Thanks, Mark. Appreciate it. So the first question, just to clarify, when we said the second half of the year, that's the sort of completed analysis or the analysis of the completed 20 patient expansion. The next update we'll be providing is at an upcoming oncology conference. So that could be midyear. We're not going to wait until second half of the year to release an update. So what we're referring to the second half is that's all 20 patients completed surveyed, et cetera, a more deeper a ...

WASHINGTON, D.C. 20549 Cue Biopharma, Inc. 02135 (ZipCode) Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act): Yes ☐ No ☒ The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant, as of the last business day of the registrant's most recently completed second fiscal quarter, was approximately $82.1 million (based on the closing price of the registrant's common stock on June 30, 2022 of $2.49 per share). ...